Rebound after Paxlovid; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Rebound after Paxlovid) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031B21A, 026L20A and 011J20A) for COVID-19 vaccination.     Concurrent medical conditions included COPD, Hypertension and Drug allergy. Concomitant products included METOPROLOL from January 2011 to an unknown date for an unknown indication.   On 23-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-May-2022 at 10:30 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (Rebound after Paxlovid). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 09-May-2022 to 13-May-2022 for COVID-19 vaccination, at a dose of 1 dosage form. At the time of the report, COVID-19 (Rebound after Paxlovid) was resolving. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 14-May-2022, SARS-CoV-2 test: positive (Positive) positive.         The 1st, 2nd and 3rd Moderna vaccines were given at 04:00 pm, 03:45 pm and 04:00 pm respectively. The patient experienced rebound after Paxlovid.  Company comment- This spontaneous case reported by a consumer, concerns a 72 year old  female patient, with  concurrent illness with  COPD and Hypertension, who experienced the unexpected, non-serious AESI of covid 19 Infection unknown days, after receiving the 3 dose of Modena mRNA1273 vaccine in the covid 19 vaccination series. Patient previously received the 2 primary doses with Moderna vaccines. Patient was treated with PAXLOVID for 5 days from 09-May-2022 to 13-May-2022. On 14-May-2022, SARS-CoV-2 test was positive. Details of, clinical course, labs, diagnostic investigations and treatment were not provided. Ongoing Covid 19 pandemia could be considered as a confounder to the event. Event is resolving. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed as per medical judgement.; Sender's Comments: This spontaneous case reported by a consumer, concerns a 72 year old  female patient, with  concurrent illness with  COPD and Hypertension, who experienced the unexpected, non-serious AESI of covid 19 Infection unknown days, after receiving the 3 dose of Modena mRNA1273 vaccine in the covid 19 vaccination series. Patient previously received the 2 primary doses with Moderna vaccines. Patient was treated with PAXLOVID for 5 days from 09-May-2022 to 13-May-2022. On 14-May-2022, SARS-CoV-2 test was positive. Details of, clinical course, labs, diagnostic investigations and treatment were not provided. Ongoing Covid 19 pandemia could be considered as a confounder to the event. Event is resolving. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed as per medical judgement.